Clinical Trial

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of HIPEC combined with NIPS and tislelizumab conversion therapy for gastric/gastroesophageal junction cancer with positive cytology alone (CY1P0) or a Peritoneal Carcinomatosis Index (PCI) ≤10
Trial Details
NCT Number NCT07304258
Lead Sponsor Hebei Medical University
Conditions Gastric Cancer Peritoneal Metastases
Enrollment 30 participants
Start Date 2025-12-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-26